(Q44048920)

29 November 2017

title

Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. (English)

1 reference

adaptive radiation therapy

29 November 2017

main subject

0 references

1 reference

Barbara Fisher

1

1 reference

29 November 2017

M Won

2

1 reference

29 November 2017

David Macdonald

3

1 reference

29 November 2017

Douglas W Johnson

4

1 reference

29 November 2017

Wilson Roa

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

International Journal of Radiation Oncology Biology Physics

29 November 2017

published in

1 reference

29 November 2017

volume

53

1 reference

29 November 2017

issue

4

1 reference

29 November 2017

page(s)

980-986

1 reference

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902817-1

7 January 2021

10.1016/S0360-3016(02)02817-1

Identifiers

DOI

1 reference

29 November 2017

1 reference